Vaccine trials essential to evaluate effectiveness against new COVID-19 variants: GlobalData Read more
Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or refractory marginal zone lymphoma, follicular lymphoma Read more